JAFRON(SZ:300529) Sou Hu Cai Jing·2025-05-19 09:43Core Viewpoint - The company Jianfan Bio is experiencing a decline in revenue and net profit, with a significant drop in both metrics year-on-year, while its stock performance shows a low price-to-earnings ratio compared to the industry average. Group 1: Company Performance - Jianfan Bio's stock closed at 22.07 yuan, up 1.42%, with a rolling PE ratio of 24.34, marking a new low in 14 days, and a total market capitalization of 17.625 billion yuan [1] - The latest quarterly report for Q1 2025 shows the company achieved operating revenue of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, down 33.71%, with a gross profit margin of 80.74% [2] Group 2: Industry Comparison - The average PE ratio for the medical device industry is 49.26, with a median of 36.71, placing Jianfan Bio at the 55th position in the industry ranking [1][3] - The industry average market capitalization is 105.99 billion yuan, while the median is 47.70 billion yuan, indicating Jianfan Bio's market cap is significantly lower than both the average and median [3] Group 3: Capital Flow - On May 19, 2023, Jianfan Bio saw a net inflow of 12.5401 million yuan in main funds, with a total inflow of 15.1556 million yuan over the past five days, indicating a generally positive capital flow trend [1]